Rhodia appoints vp of r&d

Louis Neltner moves into the role from McKinsey

International chemistry company Rhodia has appointed Louis Neltner as vice president, research and development, who also becomes a member of the Group’s Management Committee.

Neltner holds a PhD in Physics and is an engineer from France’s Corps des Mines. He started his career in 1999 at the French Telecommunications Regulatory Authority (ART), then moved to the general Inspectorate of Finance. He has been a manager at McKinsey since 2004.

You may also like

Ingredients

Rhodia to sell salicylic and acetaminophen activities to Novacap

Last remaining pharmaceutical chemistry business in the Group
Ingredients

Solvay to buy Rhodia for €3.4bn

Aims to expand business in emerging markets
Ingredients

Rhodia seeks 40% growth by 2015

Will reorganise into eleven global business units
Manufacturing

Rhodia enhances industrial footprint with key investments

Speciality surfactant supplier aims to strengthen global business
Ingredients

Rhodia buys China’s Feixiang Chemicals

Amines and surfactants business to double within next five years
Regulatory

Pipeline antipsychotic drugs to drive next market growth, says Datamonitor

<p>Atypical antipsychotics will be the engine that drives growth in this developed market, according to Datamonitor. With a global value of around US$22bn in 2008 - and the leading drug class in the US - the commercial opportunity for antipsychotics is considerable.</p>
Drug Delivery

Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody

The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Subscribe now